Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01368276 | An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma | completed | Phase 3 | 31 | BioVex LimitedINDUSTRY | 2 | Dec 18, 2015 | clinicaltrials |
| NCT00477906 | M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma | unknown | Phase 3 | 387 | AVAX TechnologiesINDUSTRY | 0 | Dec 3, 2015 | clinicaltrials |
| NCT00110019 |
| Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery |
| completed |
| Phase 3 |
| 823 |
| National Cancer Institute (NCI)NIH |
| 2 |
| Oct 19, 2015 |
| clinicaltrials |
| NCT00275496 | Multicenter Selective Lymphadenectomy Trial (MSLT) | completed | Phase 3 | 2,001 | Saint John's Cancer InstituteOTHER | 0 | Sep 2, 2015 | clinicaltrials |
| NCT01729663 | Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients | unknown | Phase 2 / Phase 3 | 108 | Laboratorio Pablo Cassara S.R.L.INDUSTRY | 1 | Sep 2, 2015 | clinicaltrials |
| NCT00006237 | S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma | completed | Phase 3 | 432 | SWOG Cancer Research NetworkNETWORK | 2 | Mar 25, 2015 | clinicaltrials |
| NCT00006249 | Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma | unknown | Phase 3 | 1,258 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 18 | Feb 10, 2015 | clinicaltrials |
| NCT00324155 | Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma | completed | Phase 3 | 681 | Bristol-Myers SquibbINDUSTRY | 25 | Nov 3, 2014 | clinicaltrials |
| NCT00111007 | A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma | completed | Phase 3 | 270 | BayerINDUSTRY | 7 | Oct 31, 2014 | clinicaltrials |
| NCT00522834 | Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma | terminated | Phase 3 | 630 | Synta Pharmaceuticals Corp.INDUSTRY | 8 | Mar 4, 2014 | clinicaltrials |
| NCT00004196 | Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis | completed | Phase 3 | 3,000 | University of Alabama at BirminghamOTHER | 1 | Jan 20, 2014 | clinicaltrials |
| NCT00002767 | Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma | unknown | Phase 3 | 300 | GlaxoSmithKlineINDUSTRY | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00016263 | Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma | completed | Phase 3 | — | Genta IncorporatedINDUSTRY | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00002892 | Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma | completed | Phase 3 | 1,000 | Institute of Cancer Research, United KingdomOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00039234 | Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver | unknown | Phase 3 | — | Maxim PharmaceuticalsINDUSTRY | 4 | Dec 18, 2013 | clinicaltrials |
| NCT00395070 | A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma | completed | Phase 3 | 390 | VicalINDUSTRY | 14 | Sep 13, 2013 | clinicaltrials |
| NCT00002455 | Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma | unknown | Phase 3 | — | Centro Oncologico de ExcelenciaOTHER | 1 | Aug 7, 2013 | clinicaltrials |
| NCT00003789 | Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg | completed | Phase 3 | 216 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00287196 | Immediate Radiotherapy or Observation After Surgery for Melanoma Involving Lymph Nodes | completed | Phase 3 | 250 | Trans Tasman Radiation Oncology GroupOTHER | 4 | Jun 25, 2013 | clinicaltrials |
| NCT00072124 | Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma | completed | Phase 3 | — | National Cancer Institute (NCI)NIH | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00671918 | Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma | completed | Phase 3 | 186 | Navidea BiopharmaceuticalsINDUSTRY | 2 | Jun 17, 2013 | clinicaltrials |
| NCT01106040 | Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes | completed | Phase 3 | 163 | Navidea BiopharmaceuticalsINDUSTRY | 1 | Jun 17, 2013 | clinicaltrials |
| NCT00447356 | High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma | withdrawn | Phase 3 | 0 | Hackensack Meridian HealthOTHER | 1 | May 13, 2013 | clinicaltrials |
| NCT01013623 | Stage IV Surgery Versus Best Medical Therapy(STG4SURG) | terminated | Phase 3 | 12 | Saint John's Cancer InstituteOTHER | 5 | Sep 26, 2012 | clinicaltrials |
| NCT00020839 | Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain | terminated | Phase 3 | 23 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 11 | Sep 24, 2012 | clinicaltrials |
| NCT00036816 | Vaccine Therapy in Treating Patients With Melanoma of the Eye | terminated | Phase 3 | 13 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Sep 24, 2012 | clinicaltrials |
| NCT00110123 | Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma | terminated | Phase 3 | 171 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Sep 24, 2012 | clinicaltrials |
| NCT00039000 | Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma | completed | Phase 3 | 350 | Agenus Inc.INDUSTRY | 9 | Sep 7, 2012 | clinicaltrials |
| NCT00257205 | CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy | completed | Phase 3 | 655 | AstraZenecaINDUSTRY | 21 | Jul 2, 2012 | clinicaltrials |
| NCT00434057 | Evaluation of Pigmented Skin Lesions With MelaFind(R) System | completed | Phase 3 | 1,383 | MELA Sciences, Inc.INDUSTRY | 1 | Feb 14, 2012 | clinicaltrials |
| NCT00002882 | Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma | completed | Phase 3 | 140 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 13, 2011 | clinicaltrials |
| NCT00002763 | High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma | unknown | Phase 3 | 1,000 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 21 | Nov 16, 2011 | clinicaltrials |
| NCT00518895 | Trial of Dacarbazine With or Without Genasense in Advanced Melanoma(AGENDA) | completed | Phase 3 | 300 | Genta IncorporatedINDUSTRY | 12 | Nov 7, 2011 | clinicaltrials |
| NCT00094653 | MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma | completed | Phase 3 | 1,783 | Bristol-Myers SquibbINDUSTRY | 13 | Jul 11, 2011 | clinicaltrials |
| NCT01259934 | Nordic Adjuvant IFN Melanoma Trial | completed | Phase 3 | 855 | Karolinska InstitutetOTHER | 1 | Dec 14, 2010 | clinicaltrials |
| NCT00221702 | PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial)(EADO) | completed | Phase 3 | 898 | University Hospital, BordeauxOTHER | 1 | Oct 13, 2010 | clinicaltrials |
| NCT00811200 | Treatment Of Radiation Retinopathy Trial(TORR) | unknown | Phase 2 / Phase 3 | 220 | Leiden University Medical CenterOTHER | 0 | Jul 2, 2009 | clinicaltrials |
| NCT00005052 | Vaccine Therapy in Treating Patients With Primary Stage II Melanoma | unknown | Phase 3 | — | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 18 | Feb 9, 2009 | clinicaltrials |
| NCT00779714 | Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC(ChemoSensMM) | unknown | Phase 3 | 360 | University of WuerzburgOTHER | 1 | Oct 24, 2008 | clinicaltrials |
| NCT00003647 | Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 3 | — | VicalINDUSTRY | 1 | Jul 25, 2008 | clinicaltrials |
| NCT00001296 | A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma | completed | Phase 3 | 122 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00226408 | Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon | unknown | Phase 3 | 600 | Dermatologic Cooperative Oncology GroupOTHER | 1 | Jun 21, 2006 | clinicaltrials |
| NCT00052130 | Vaccine Therapy for Patients With Stage III Melanoma | unknown | Phase 3 | 1,118 | CancerVax CorporationINDUSTRY | 13 | Jun 24, 2005 | clinicaltrials |
| NCT00052156 | Vaccine Therapy for Patients With Stage IV Melanoma | unknown | Phase 3 | 670 | CancerVax CorporationINDUSTRY | 13 | Jun 24, 2005 | clinicaltrials |
| NCT00055562 | Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma | completed | Phase 2 / Phase 3 | 274 | Celgene CorporationINDUSTRY | 2 | Jun 24, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Dec 18, 2015source: clinicaltrials